NeuroSearch Planning Phase II For MMRI With Fast Onset Of Action
Executive Summary
NeuroSearch is planning a Phase II dosage study for its mixed monoamine re-uptake inhibitor, NS2389, which the Danish company said has demonstrated a faster antidepressant effect in animal models than that shown by serotonin re-uptake inhibitors using the same model. The study is slated to begin before the end of 1998.